Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vabicaserin · 3 trials · 2 indications
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210; higher score indicates greater severity.
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210; higher score indicates greater severity.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | 4mg/day |
| 3 | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| vabicaserin | DRUG | This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study |
| risperidone | DRUG | - |
| placebo | OTHER | - |
Inclusion Criteria: * Generally healthy, men and women, aged 18 to 65. * Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year. * Ability to remain hospitalized for the duration of the screening period and for 4 weeks of ...
Vabicaserin is an investigational small molecule being developed by Pfizer, Inc. (NYSE: PFE). It has been studied in schizophrenia and in healthy subjects. Vabicaserin is in clinical development, with completed trials in Phase 1 and Phase 2.
Vabicaserin has been studied for use in schizophrenia, as well as in healthy subjects for bioavailability and formulation studies. It is an investigational drug and has not been approved by the FDA.
Vabicaserin is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE.
Vabicaserin has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug, meaning it is still in clinical development and has not been approved for any use.
Vabicaserin has been studied in clinical trials including NCT00541996, a Phase 1 study comparing bioavailability of oral formulations in schizophrenia patients; NCT00563706, a Phase 2 study in subjects with schizophrenia; and NCT00928551, a Phase 1 comparative formulation study in healthy subjects.
Vabicaserin is not known by any other names. It is a distinct investigational compound developed by Pfizer.